Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
—
−4.08USD
−21.67 MUSD
68.00 KUSD
2.98 M
About Eterna Therapeutics Inc.
Sector
CEO
Sanjeev Luther
Headquarters
Cambridge
Website
Employees (FY)
8
Founded
1984
FIGI
BBG000CX5677
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ERNA is 1.83 USD — it has increased by 2.24% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Eterna Therapeutics Inc. stocks are traded under the ticker ERNA.
Eterna Therapeutics Inc. is going to release the next earnings report on May 22, 2024. Keep track of upcoming events with our Earnings Calendar.
ERNA stock is 7.65% volatile and has beta coefficient of 0.81. Check out the list of the most volatile stocks — is Eterna Therapeutics Inc. there?
ERNA earnings for the last quarter are −2.40 USD per share, whereas the estimation was −3.20 USD resulting in a 25.00% surprise. The estimated earnings for the next quarter are −2.60 USD per share. See more details about Eterna Therapeutics Inc. earnings.
Eterna Therapeutics Inc. revenue for the last quarter amounts to 4.58 M USD despite the estimated figure of 6.14 M USD. In the next quarter revenue is expected to reach 6.20 M USD.
Yes, you can track Eterna Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
ERNA stock has fallen by 10.73% compared to the previous week, the month change is a 19.74% fall, over the last year Eterna Therapeutics Inc. has showed a 37.19% decrease.
ERNA net income for the last quarter is −6.15 M USD, while the quarter before that showed −5.59 M USD of net income which accounts for −10.05% change. Track more Eterna Therapeutics Inc. financial stats to get the full picture.
Today Eterna Therapeutics Inc. has the market capitalization of 9.68 M, it has decreased by 0.93% over the last week.
No, ERNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ERNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eterna Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 8.00 employees. See our rating of the largest employees — is Eterna Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eterna Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eterna Therapeutics Inc. stock shows the sell signal. See more of Eterna Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eterna Therapeutics Inc. EBITDA is −19.55 M USD, and current EBITDA margin is −28.75 K%. See more stats in Eterna Therapeutics Inc. financial statements.